TG101348

Indications: - polycythemia vera Pharmacokinetics: - IC50 3 nM Adverse effects: - not tested in humans - no toxicity apparent in mice Mechanism of action: - inhibits JAK2

General

antineoplastic agent (chemotherapeutic agent) enzyme inhibitor

References

- Wernig G et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008 Apr; 13:311 PMID: 18394554